Zentalis Pharmaceuticals develops azenosertib, an experimental oral cancer drug for ovarian cancer and other tumors. It last closed at $1.49 on Nov 17, down 6.88% on the day. The average 12-month price target from 3 analysts is $8.00 (+436.9% from the last close), with a high of $10.00 and a low of $6.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Each firm's latest rating on ZNTL in the past 90 days
Average 12-month target
$8.00
▲ 436.9% upside
Based on 3 analysts who set a price target on ZNTL in the past 90 days. The average target is $8.00, with a high of $10.00 and a low of $6.00, compared with the last close of $1.49.
Low $6.00Avg $8.00High $10.00
Blue marker: last close $1.49
Highest target$10.00
Average target$8.00
Lowest target$6.00
Latest rating changes
WedbushUpgrade
Nov 10Buy$6
HC Wainwright & Co.Reiterated
Oct 19Buy$10
Leerink PartnersAssumed coverage
Oct 5Buy$8
Rodman & RenshawInitiated
Jul 23Buy$11
MizuhoInitiated
Jul 17Buy$8
Date
Firm
Action
Rating
Price target
Nov 10
Wedbush
Upgrade
Buy
$6
Oct 19
HC Wainwright & Co.
Reiterated
Buy
$10
Oct 5
Leerink Partners
Assumed coverage
Buy
$8
Jul 23
Rodman & Renshaw
Initiated
Buy
$11
Jul 17
Mizuho
Initiated
Buy
$8
Loading…
Technical Analysis
ZNTL · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 27% below its 20 day and 63% below its 50 day average. It is 127% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot S1 at $1.43, and the nearest resistance the Pivot at $1.54.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.2%/day
Key levels
$6.9552 week high+366.4%
$3.40100 day average+128.2%
$3.39200 day average+127.5%
$2.4350 day average+63.1%
$1.98Swing high (Nov 10)+32.9%
$1.8920 day average+26.8%
$1.60Pivot R1+7.4%
$1.54Pivot+3.4%
$1.49Last close
$1.43Pivot S1−4.0%
$1.2852 week low−14.1%
Indicators
RSI (14)
26.69
Oversold below 30
Oversold
MACD
-0.25
Above its signal line
Bullish
Stochastic
6.5
Near the bottom of its range
Oversold
ADX (14)
48.6
Strong downtrend
Williams %R
-98.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-133.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−16.3%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 12.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 38.6%/day
Key levels
$6.9552 week high+366.4%
$3.40100 day average+128.2%
$3.39200 day average+127.5%
$2.4350 day average+63.1%
$1.98Swing high (Nov 10)+32.9%
$1.8920 day average+26.8%
$1.60Pivot R1+7.4%
$1.54Pivot+3.4%
$1.49Last close
$1.43Pivot S1−4.0%
$1.2852 week low−14.1%
Indicators
RSI (14)
32.41
Weak, oversold below 30
Neutral
MACD
-0.52
Below its signal line
Bearish
Stochastic
1.8
Near the bottom of its range
Oversold
ADX (14)
26.0
Trending down
Williams %R
-99.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-115.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−57.5%
Change over 10 sessions
Bearish
ATR (14)
$0.58
Typical daily range, 38.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZNTL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ZNTL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ZNTL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ZNTL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZNTL is in one of them and how their past ZNTL trades turned out.
Zentalis Pharmaceuticals is a drug developer based in San Diego, California. Its main focus is azenosertib, an experimental oral medicine that works by blocking a cell protein called WEE1. The drug is being developed for patients with ovarian cancer and possibly other tumor types. The company is testing it in clinical trials, with its current focus on patients with platinum-resistant ovarian cancer whose tumors show high levels of Cyclin E1 protein.